166 related articles for article (PubMed ID: 31739839)
1. Safety, pharmacokinetics and efficacy of donafenib in treating advanced hepatocellular carcinoma: report from a phase 1b trial.
Liu J; Li X; Zhang H; Chen G; Chen H; Hu Y; Niu J; Ding Y
Pharmazie; 2019 Nov; 74(11):688-693. PubMed ID: 31739839
[No Abstract] [Full Text] [Related]
2. Sorafenib: a review of its use in advanced hepatocellular carcinoma.
Keating GM; Santoro A
Drugs; 2009; 69(2):223-40. PubMed ID: 19228077
[TBL] [Abstract][Full Text] [Related]
3. A Phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours.
Li X; Qiu M; Wang S; Zhu H; Feng B; Zheng L
Cancer Chemother Pharmacol; 2020 Mar; 85(3):593-604. PubMed ID: 32008115
[TBL] [Abstract][Full Text] [Related]
4. Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.
Qin S; Bi F; Gu S; Bai Y; Chen Z; Wang Z; Ying J; Lu Y; Meng Z; Pan H; Yang P; Zhang H; Chen X; Xu A; Cui C; Zhu B; Wu J; Xin X; Wang J; Shan J; Chen J; Zheng Z; Xu L; Wen X; You Z; Ren Z; Liu X; Qiu M; Wu L; Chen F
J Clin Oncol; 2021 Sep; 39(27):3002-3011. PubMed ID: 34185551
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
[TBL] [Abstract][Full Text] [Related]
6. Donafenib in Progressive Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Results of a Randomized, Multicenter Phase II Trial.
Lin YS; Yang H; Ding Y; Cheng YZ; Shi F; Tan J; Deng ZY; Chen ZD; Wang RF; Ji QH; Huang R; Li LF
Thyroid; 2021 Apr; 31(4):607-615. PubMed ID: 32907500
[No Abstract] [Full Text] [Related]
7. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
Strumberg D; Richly H; Hilger RA; Schleucher N; Korfee S; Tewes M; Faghih M; Brendel E; Voliotis D; Haase CG; Schwartz B; Awada A; Voigtmann R; Scheulen ME; Seeber S
J Clin Oncol; 2005 Feb; 23(5):965-72. PubMed ID: 15613696
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
El-Khoueiry AB; Sangro B; Yau T; Crocenzi TS; Kudo M; Hsu C; Kim TY; Choo SP; Trojan J; Welling TH; Meyer T; Kang YK; Yeo W; Chopra A; Anderson J; Dela Cruz C; Lang L; Neely J; Tang H; Dastani HB; Melero I
Lancet; 2017 Jun; 389(10088):2492-2502. PubMed ID: 28434648
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.
Furuse J; Ishii H; Nakachi K; Suzuki E; Shimizu S; Nakajima K
Cancer Sci; 2008 Jan; 99(1):159-65. PubMed ID: 17953709
[TBL] [Abstract][Full Text] [Related]
12. Donafenib: First Approval.
Keam SJ; Duggan S
Drugs; 2021 Nov; 81(16):1915-1920. PubMed ID: 34591285
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
[TBL] [Abstract][Full Text] [Related]
14. PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma.
Abou-Alfa GK; Chan SL; Lin CC; Chiorean EG; Holcombe RF; Mulcahy MF; Carter WD; Patel K; Wilson WR; Melink TJ; Gutheil JC; Tsao CJ
Cancer Chemother Pharmacol; 2011 Aug; 68(2):539-45. PubMed ID: 21594722
[TBL] [Abstract][Full Text] [Related]
15. Donafenib in hepatocellular carcinoma.
Chen R; Ielasi L; di Carlo A; Tovoli F
Drugs Today (Barc); 2023 Feb; 59(2):83-90. PubMed ID: 36811408
[TBL] [Abstract][Full Text] [Related]
16. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
Strumberg D; Clark JW; Awada A; Moore MJ; Richly H; Hendlisz A; Hirte HW; Eder JP; Lenz HJ; Schwartz B
Oncologist; 2007 Apr; 12(4):426-37. PubMed ID: 17470685
[TBL] [Abstract][Full Text] [Related]
17. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.
Rimassa L; Assenat E; Peck-Radosavljevic M; Pracht M; Zagonel V; Mathurin P; Rota Caremoli E; Porta C; Daniele B; Bolondi L; Mazzaferro V; Harris W; Damjanov N; Pastorelli D; Reig M; Knox J; Negri F; Trojan J; López López C; Personeni N; Decaens T; Dupuy M; Sieghart W; Abbadessa G; Schwartz B; Lamar M; Goldberg T; Shuster D; Santoro A; Bruix J
Lancet Oncol; 2018 May; 19(5):682-693. PubMed ID: 29625879
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
[TBL] [Abstract][Full Text] [Related]
20. Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma.
Lee SJ; Lee J; Park SH; Park JO; Park YS; Kang WK; Lee J; Yim DS; Lim HY
Invest New Drugs; 2012 Aug; 30(4):1540-7. PubMed ID: 21695438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
